It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...

Ryan Kessinger, Sr., 5-10, S, Jake Starr, Sr., 6-1, OH, Mario Romagni, Sr., 6-0, OH, Tony Masters, Sr., 6-5, MH, Maddox Fuenes, So., 6-5, MH, Levi Rohl, Sr., 5-11, OPP, Trent Hornak, Sr., 5-9, L ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

As the guests of honor, they walked down a red carpet, free of kids for the night, to enjoy time with others in the community ...

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

Tyler ISD Police Department arrested three employees on Friday. Dr. Marty Crawford said it did involve a student with ...

Corcept Therapeutics (NasdaqCM:CORT) recently announced successful results from its ROSELLA trial for relacorilant plus nab-paclitaxel, indicating a notable positive stride in treatment for ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.